Heat Biologics Inc (HTBX) Short Interest Up 52.1% in February
Heat Biologics Inc (NASDAQ:HTBX) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,007,916 shares, an increase of 52.1% from the February 15th total of 662,573 shares. Currently, 3.4% of the shares of the company are sold short. Based on an average daily volume of 2,299,772 shares, the days-to-cover ratio is presently 0.4 days.
HTBX has been the topic of several recent research reports. ValuEngine downgraded shares of Heat Biologics from a “buy” rating to a “hold” rating in a report on Tuesday, December 25th. HC Wainwright set a $6.00 price objective on shares of Heat Biologics and gave the company a “buy” rating in a report on Friday, November 16th.
Institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp bought a new stake in shares of Heat Biologics during the second quarter valued at about $111,000. Virtu Financial LLC bought a new stake in shares of Heat Biologics during the fourth quarter valued at about $55,000. Vanguard Group Inc increased its position in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 136,256 shares during the period. Vanguard Group Inc. increased its position in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 136,256 shares during the period. Finally, CVI Holdings LLC bought a new stake in shares of Heat Biologics during the fourth quarter valued at about $1,527,000. Hedge funds and other institutional investors own 16.39% of the company’s stock.
Heat Biologics Company Profile
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Featured Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.